共 178 条
[1]
Blagden SP(2020)Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial Lancet Oncol 21 969-977
[2]
Cook AD(2016)Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer N Engl J Med 374 738-748
[3]
Poole C(2014)Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial Lancet Oncol 15 396-405
[4]
Howells L(2010)Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N Engl J Med 363 943-953
[5]
McNeish IA(2017)Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009–13 BMJ 359 j4530-1427
[6]
Dean A(2011)Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials Support Care Cancer 19 1421-852
[7]
Chan JK(2019)Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study Ann Oncol 30 845-463
[8]
Brady MF(2018)Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: a longitudinal study Gynecol Oncol 149 455-186
[9]
Penson RT(2020)When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer Gynecol Oncol 159 179-1291
[10]
Huang H(2019)Quality of life outcomes following surgery for advanced ovarian cancer: a systematic review and meta-analysis Int J Gynecol Cancer 29 1285-801